ALS drug safety tracked for a full year in small patient group
NCT ID NCT05176093
Summary
This study followed 8 people with ALS (amyotrophic lateral sclerosis) for an extra 6 months to check the long-term safety of an experimental drug called Engensis. All participants had already received the drug or a placebo in a previous trial. The main goal was to monitor for any side effects or health problems that might arise from continued use of the injections over a full year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Neuromuscular Center
Austin, Texas, 78759, United States
-
Hanyang University Medical Center
Seoul, 04763, South Korea
Conditions
Explore the condition pages connected to this study.